Bryhali Generic Name & Formulations
Legal Class
Rx
General Description
Halobetasol propionate 0.01%; lotion.
Pharmacological Class
Corticosteroid.
How Supplied
Lotion—60g,100g
Manufacturer
Generic Availability
NO
Bryhali Indications
Indications
Plaque psoriasis.
Bryhali Dosage and Administration
Adult
≥18yrs: apply a thin layer to affected areas once daily; max 50g/week. Treatment lasting >8 weeks: not recommended. Discontinue when control is achieved. Do not occlude.
Children
<18yrs: not established.
Bryhali Contraindications
Not Applicable
Bryhali Boxed Warnings
Not Applicable
Bryhali Warnings/Precautions
Warnings/Precautions
Not for oral, ophthalmic, or intravaginal use. Avoid use on the face, groin, or axillae. Risk of HPA axis suppression with high-potency corticosteroids, prolonged use, application to large surface areas, occlusive use, altered skin barrier, concomitant multiple corticosteroid-containing products, liver failure, young age; discontinue gradually, reduce dose, or substitute with less potent corticosteroid if occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Treat infection if present; discontinue until resolved. Reevaluate periodically. Discontinue if allergic contact dermatitis occurs. Pregnancy. Nursing mothers: avoid nipple/areola area due to infant exposure.
Bryhali Pharmacokinetics
See Literature
Bryhali Interactions
Not Applicable
Bryhali Adverse Reactions
Adverse Reactions
Upper respiratory tract infection, application site dermatitis, hyperglycemia; local adverse reactions (eg, atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, miliaria), Cushing’s syndrome, glucosuria, HPA axis suppression (esp. in children).
Bryhali Clinical Trials
See Literature
Bryhali Note
Not Applicable
Bryhali Patient Counseling
See Literature
Images
